CA-PATIENT-SAFETY
4.4.2022 14:02:12 CEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF) will host the 8th annual World Patient Safety, Science and Technology Summit (WPSSTS) virtually April 29 and April 30, 2022. The event is co-convened by the American Society of Anesthesiologists, the European Society of Anesthesiology and Intensive Care, the International Society for Quality in Health Care and the World Federation of Societies of Anaesthesiologists. Creating a powerful forum for industry leaders and healthcare organizations to confront leading patient safety issues with actionable ideas and innovations to transform the continuum of care, the event supports PSMF’s mission to reach zero preventable patient harm and death across the world by 2030.
“The last two years have been taxing on the healthcare sector to say the least. The global pandemic placed relentless stress on health systems and medical personnel, which resulted in an increase in preventable medical errors,” said Dr. Michael Ramsay, CEO of PSMF. “Our organization is eager to bring key stakeholders together to help develop solutions to dramatically improve patient safety and eliminate preventable patient harm and death.”
The summit will include a fireside chat with patient safety luminaries, seven keynote addresses, as well as five panel sessions covering various topics in patient safety led by esteemed healthcare leaders. This year’s WPSSTS sessions focus on key issues impacting the healthcare industry, including:
- Overcoming Obstacles for Applying High Reliability Principles in Healthcare
- Embracing the Science of Human Factors to Unleash Safety Innovation in Healthcare
- Patient Advocacy: The Compass for Innovation
- How Regulation Can Support Quality and Value in Healthcare
- Healthcare Safety During the Pandemic
Attendees will have the opportunity to network with top hospital executives, patients and family members who have been impacted by medical error, public policymakers and government officials, as well as leaders across the healthcare continuum. Keynote speakers include:
- Randall Clark, MD, FASA, president of the American Society of Anesthesiologists
- Edoardo de Robertis, MD, PhD and president of the European Society of Anaesthesiology and Intensive Care (ESAIC)
- Neelam Dhingra-Kumar, MD, unit head of the WHO Patient Safety Flagship
- Carsten Engel, MD, CEO of the International Society for Quality in Health Care
- Joe Kiani, founder & immediate past chairman of the Patient Safety Movement Foundation, as well as founder, chairman & CEO of Masimo
- Peter Pronovost, MD, PhD, chief clinical transformation officer at University Hospitals
- Thomas Zeltner MD, chairman of the WHO Foundation, Geneva (Switzerland) and deputy chair of the University Council of the Medical University of Vienna (Austria)
The summit is open to anyone interested in actively planning solutions around the leading patient safety challenges that cause preventable patient deaths in hospitals and healthcare organizations worldwide. Discounted registration is offered for students, patients and family members. To register for the 2022 WPSSTS or to learn more about the event, visit: https://patient.sm/WPSSTS .
About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005206/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
